The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching

Eitemau Tebyg

• The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma
  gan: Jingwen Zhang, et al.
  Cyhoeddwyd: (2024-02-01)
• Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study
  gan: Yanjun Wang, et al.
  Cyhoeddwyd: (2025-02-01)
• Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States
  gan: Guiyuan Xiang, et al.
  Cyhoeddwyd: (2024-09-01)
• Case report: A rare case of delayed drug-induced hyponatremia in recurrent upper tract urothelial carcinoma following GC and Tislelizumab treatment
  gan: Zhi-Jie Wang, et al.
  Cyhoeddwyd: (2025-01-01)
• Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy
  gan: Meng Yang, et al.
  Cyhoeddwyd: (2024-02-01)